Market Overview
The Female Infertility Diagnosis Market covers a range of diagnostic procedures and laboratory tests designed to evaluate and identify factors contributing to female infertility. These diagnostics include ovarian reserve testing to assess egg quantity and quality, hormone testing to measure reproductive hormone levels, and hysterosalpingography to examine the uterus and fallopian tubes. The market operates within the broader reproductive health and clinical diagnostics industry, serving fertility clinics, hospitals, and diagnostic laboratories worldwide.
- •Market valued at $2.4 billion globally in 2025
- •Includes ovarian reserve testing, hormone testing, hysterosalpingography, and other diagnostic tests
- •Serves fertility clinics, hospitals, and diagnostic laboratories
Growth Drivers
Rising infertility prevalence worldwide, linked to lifestyle factors, environmental exposures, and increasing maternal age, is a primary catalyst for market expansion. Greater social acceptance and awareness of infertility treatments have encouraged more women to seek diagnostic evaluation, while improved healthcare infrastructure in developing regions has increased access to testing services. Additionally, technological advancements in diagnostic accuracy and minimally invasive testing methods have enhanced the appeal of modern infertility diagnostics.
- •Rising infertility rates driven by delayed childbearing and lifestyle factors
- •Growing awareness and reduced stigma around fertility evaluation
- •Advancements in diagnostic technology improving test accuracy and patient comfort
Segmentation and Regional Analysis
The market is segmented by test type into ovarian reserve testing, hormone testing, hysterosalpingography, and other specialized procedures, with each segment serving distinct diagnostic purposes in fertility assessment. Geographically, North America and Europe currently represent the largest market shares due to advanced healthcare infrastructure and high infertility awareness, while Asia-Pacific is expected to show the fastest growth as healthcare access expands and awareness increases.
- •Key segments: ovarian reserve testing, hormone testing, hysterosalpingography, and other tests
- •North America and Europe lead in market share due to established healthcare systems
- •Asia-Pacific emerging as a high-growth region driven by expanding healthcare access
Trends and Outlook
What are the recent trends and outlook?
The market is expected to continue its steady expansion through 2030, with the 5.8% annual growth rate reflecting sustained demand for infertility diagnostics. Integration of artificial intelligence and automation in diagnostic laboratories is anticipated to enhance testing efficiency and accuracy, while personalized medicine approaches may drive development of more targeted diagnostic panels. As fertility preservation awareness grows and egg freezing becomes more common, demand for ovarian reserve and related diagnostic testing is likely to increase further.
- •Market projected to maintain 5.8% CAGR through the forecast period
- •AI and automation adoption expected to improve diagnostic efficiency
- •Growing fertility preservation trend likely to boost demand for ovarian reserve testing
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.